Trial Profile
An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Pabinafusp alfa (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors JCR Pharmaceuticals
- 14 Feb 2024 Results published in a JCR Pharmaceuticals Media Release.
- 14 Feb 2024 According to JCR Pharmaceuticals, long-term efficacy and safety data from Japanese and Brazilian study were presented at the 20th Annual WORLDSymposium, 2024.
- 22 Jun 2023 Planned End Date changed from 31 Dec 2026 to 31 Mar 2024.